This study has two aims: 1) to characterize the effects of intravenous ketamine on neurocognitive markers in depressed patients; 2) to test the efficacy of a synergistic intervention for depression combining intravenous ketamine with neurocognitive training.
Topic Depression
Country United States of America
Visit trial
Status
Active, not recruiting
Start date
01 December 2017
End date
01 October 2023
Chance of happening
100%
Phase
Phase I
Phase II
Design
Blinded
Type
Interventional
Generation
First
Participants
150
Sex
All
Age
18- 60
Therapy
No
Trial Details
This study has two aims: 1) to characterize the effects of intravenous ketamine on neurocognitive markers in depressed patients; 2) to test the efficacy of a synergistic intervention for depression combining intravenous ketamine with neurocognitive training.NCT Number NCT03237286
Sponsors & Collaborators
National Institute of Mental HealthThis company doesn't have a full profile yet, it is linked to a clinical trial.
University of Pittsburgh
This company doesn't have a full profile yet, it is linked to a clinical trial.
Measures Used
Montgomery-Asberg Depression Rating ScaleA ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.
Quick Inventory of Depressive Symptomatology
The Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-SR16) is a self-report tool designed to screen for depression and measure changes in the severity of symptoms.